repaglinide

Brand: Prandin

Prototype Drug
Drug Class: meglitinide
Drug Family: antidiabetic
Subclass: short-acting insulin secretagogue
Organ Systems: endocrine

Mechanism of Action

Binds to a distinct site on the SUR1 subunit of ATP-sensitive potassium channels in beta cells, causing rapid channel closure, depolarization, and insulin secretion. Has a very short duration compared to sulfonylureas, making it suitable for mealtime-only glucose control.

SUR1 subunit of KATP channels (pancreatic beta cells)

Indications

  • type 2 diabetes mellitus (mealtime insulin secretagogue)

Contraindications

  • type 1 diabetes
  • DKA
  • concurrent gemfibrozil use (major interaction)

Adverse Effects

Common

  • hypoglycemia (meal-related)
  • weight gain
  • headache
  • back pain

Serious

  • severe hypoglycemia (if meal is skipped)
  • hepatotoxicity (rare)

Pharmacokinetics (ADME)

Absorption rapidly absorbed; peak within 1 hour; take 0–30 min before meals
Distribution 98% protein bound
Metabolism hepatic via CYP3A4 and CYP2C8
Excretion fecal (90%) via bile; minimal renal
Half-life 1 hour
Onset 30 minutes
Peak 1 hour
Duration 3–4 hours
Protein Binding 98%
Vd low

Drug Interactions

Drug / Agent Mechanism Severity
gemfibrozil CYP2C8 and OATP1B1 inhibition dramatically increases repaglinide levels (8-fold); contraindicated contraindicated
clarithromycin CYP3A4 inhibition increases repaglinide levels major

Nursing Considerations

  1. Take 0–30 minutes before each meal; if a meal is skipped, skip the dose to prevent hypoglycemia.
  2. The gemfibrozil interaction is contraindicated and clinically critical — always check for this combination.
  3. Monitor liver function; avoid in significant hepatic impairment (primary route of elimination).
  4. Flexible dosing (2–4 times daily based on meal schedule) can accommodate irregular eating patterns better than fixed-dose sulfonylureas.

Clinical Pearls

  • Meglitinides are taken with each meal, offering flexible dosing for patients with irregular eating schedules; if a meal is skipped, the dose must be skipped to avoid hypoglycemia.
  • The gemfibrozil-repaglinide interaction is a landmark CYP2C8/OATP interaction used frequently in pharmacology education — coadministration is absolutely contraindicated.

Safety Profile

Pregnancy avoid
Lactation avoid
Renal Adjustment Not required
Hepatic Adjustment Required
TDM Not required

Concordance Terms

Cross-referenced clinical concepts — click any term to see all content where it appears.